{"id":294,"date":"2012-02-01T13:30:00","date_gmt":"2012-02-01T13:30:00","guid":{"rendered":"https:\/\/nolato.wpengine.com\/?mfn_news=financial-position-remains-strong"},"modified":"2012-02-01T13:30:00","modified_gmt":"2012-02-01T13:30:00","slug":"financial-position-remains-strong","status":"publish","type":"mfn_news","link":"https:\/\/temporary.nolato.com\/sv\/mfn_news\/financial-position-remains-strong\/","title":{"rendered":"Financial position remains strong"},"content":{"rendered":"
<\/strong><\/div>\n

In today\u2019s year-end report, Nolato reports sales for the fourth quarter of 2011 of SEK 734 million (864). Operating income (EBITA) was SEK 48 million (63) and the EBITA margin was 6.5% (7.3). <\/span><\/strong><\/p>\n

Nolato Medical\u2019s sales totalled SEK 230 million (235), operating income amounted to SEK 28 million (28) and the EBITA margin was 12.2% (11.9). <\/span><\/p>\n

\u201cExcluding currency conversion effects, Nolato Medical\u2019s sales were in line with the previous year,\u201d says Hans Porat, President and CEO of Nolato. \u201cProduct sales during the fourth quarter developed in line with the market, while sales within projects fell from a high level. We believe that the lower sales from projects will continue during the impending quarters.\u201d <\/span><\/p>\n

Nolato Telecom\u2019s sales fell by 45% to SEK 207 million (377). Operating income (EBITA) was SEK 4 million (24) and the EBITA margin was 1.9% (6.4). <\/span><\/p>\n

\u201cDemand for the business area\u2019s product portfolio remains weak and the focus has therefore been placed on developing the product portfolio ahead of 2012,\u201d comments Hans Porat.\u201d <\/span><\/p>\n

Nolato Industrial\u2019s sales rose by 18% to SEK 299 million (253). Operating income (EBITA) rose by 33% to SEK 24 million (18). The EBITA margin was 8.0% (7.1). <\/span><\/p>\n

\u201cStrong demand, advanced market positions and new products contributed to an increase in sales,\u201d adds Mr Porat. \u201cA high level of capacity utilisation and high productivity had a positive impact on the margin.\u201d <\/span><\/p>\n

Consolidated sales for 2011 as a whole totalled SEK 2,977 million (3,375). Operating income (EBITA) was SEK 199 million (262) and earnings per share were SEK 5.02 (7.11). <\/span><\/p>\n

Nolato enjoys a strong financial position. Net debt stood at SEK 82 million (34), with an equity\/assets ratio of 54% (50). Cash flow during 2011 was SEK 112 million (230, excluding acquisitions and property disposed of). <\/span><\/p>\n

The Board proposes an ordinary dividend for 2011 of SEK 3.00 per share (3.00) and an extra dividend of SEK 2.00 (3.00), in total SEK 5.00 (6.00). The AGM will be held on 24 April 2012 in Grevie, Sweden.<\/span><\/p>\n<\/p>\n

——<\/span><\/p>\n

For further information, please contact: <\/span><\/em>
Hans Porat, President and CEO, 46 431 442294 <\/span><\/em>
Per-Ola Holmstr\u00f6m, CFO, 46 431 442293<\/span><\/em><\/p>\n

The Nolato Group is a high-tech developer and manufacturer of polymer product systems for leading customers in medical technology, telecom, hygiene, automotive products and other \u00adselected industrial sectors. Nolato\u2019s shares are quoted on the Nasdaq OMX Nordic Exchange, Stockholm Mid Cap, \u00adInformation Technology. www.nolato.com<\/a><\/span><\/em><\/p>\n

Nolato AB discloses the information provided herein pursuant to the Securities Markets Act and\/or the Financial Instruments Trading Act. The information was submitted for publication at 2,30 pm on 1 February 2012.<\/span><\/em><\/p>\n

\n

<\/strong><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

In today\u2019s year-end report, Nolato reports sales for the fourth quarter of 2011 of SEK 734 million (864). Operating income (EBITA) was SEK 48 million (63) and the EBITA margin was 6.5% (7.3). Nolato Medical\u2019s sales totalled SEK 230 million (235), operating income amounted to SEK 28 million (28) and the EBITA margin was 12.2%… Continue reading Financial position remains strong<\/span><\/a><\/p>\n","protected":false},"template":"","class_list":["post-294","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim-q4","entry"],"translation":{"provider":"WPGlobus","version":"3.0.0","language":"sv","enabled_languages":["en","es","de","fr","ru","sv"],"languages":{"en":{"title":true,"content":true,"excerpt":false},"es":{"title":false,"content":false,"excerpt":false},"de":{"title":false,"content":false,"excerpt":false},"fr":{"title":false,"content":false,"excerpt":false},"ru":{"title":false,"content":false,"excerpt":false},"sv":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/temporary.nolato.com\/sv\/wp-json\/wp\/v2\/mfn_news\/294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/temporary.nolato.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/temporary.nolato.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/temporary.nolato.com\/sv\/wp-json\/wp\/v2\/media?parent=294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}